2 型糖尿病中的心血管疾病：迈向个体化管理的进展。
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management.
机构信息
Department of Endocrinology, The First Hospital of Lanzhou University, No. 1 West Donggang Road, Lanzhou, Gansu, 730000, People's Republic of China.
The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, China.
出版信息
Cardiovasc Diabetol. 2022 May 14;21(1):74. doi: 10.1186/s12933-022-01516-6.
Abstract
Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control and cardiovascular risk management (strict blood pressure and lipid control), together with recently developed glucose-lowering agents and lipid-lowering drugs. This review mainly addresses the important issues affecting the choice of antidiabetic agents and lipid, blood pressure and antiplatelet treatments considering the cardiovascular status of the patient. Finally, we also discuss the changes in therapy principles underlying CVDs in T2DM.
摘要
心血管疾病（CVDs）是 2 型糖尿病（T2DM）患者死亡的主要原因，尤其是在低收入和中等收入国家。为了有效预防 T2DM 患者发生 CVDs，人们一直在努力探索新的预防方法，包括个体化血糖控制和心血管风险管理（严格的血压和血脂控制），以及最近开发的降血糖药物和降脂药物。本综述主要针对考虑患者心血管状况时影响选择抗糖尿病药物和调脂、降压及抗血小板治疗的重要问题进行讨论。最后，我们还讨论了 T2DM 患者 CVD 治疗原则的变化。
相似文献
1
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management.2 型糖尿病中的心血管疾病：迈向个体化管理的进展。
Cardiovasc Diabetol. 2022 May 14;21(1):74. doi: 10.1186/s12933-022-01516-6.
2
Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications.2型糖尿病合并心血管并发症患者血糖控制与抗糖尿病药物之间的关联。
Drug Des Devel Ther. 2015 Aug 18;9:4735-49. doi: 10.2147/DDDT.S87294. eCollection 2015.
3
Severe hypoglycemia as a preventable risk factor for cardiovascular disease in patients with type 2 diabetes mellitus.严重低血糖是 2 型糖尿病患者心血管疾病的可预防风险因素。
Korean J Intern Med. 2021 Mar;36(2):263-270. doi: 10.3904/kjim.2020.327. Epub 2021 Jan 8.
4
Combined use of polypill components in patients with type 2 diabetes mellitus.联合使用 2 型糖尿病患者的多效药丸成分。
Eur J Prev Cardiol. 2018 Sep;25(14):1523-1531. doi: 10.1177/2047487318789494. Epub 2018 Jul 23.
5
Antidiabetic Drugs as Antihypertensives: New Data on the Horizon.抗糖尿病药物作为抗高血压药物：新的前景数据。
Curr Vasc Pharmacol. 2017;16(1):70-78. doi: 10.2174/1570161115666171010122332.
6
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.恩格列净心血管结局研究（EMPA-REG）及其他降糖药物心血管结局试验：对2型糖尿病未来治疗策略的启示
Clin Ther. 2016 Jun;38(6):1288-1298. doi: 10.1016/j.clinthera.2016.04.037. Epub 2016 May 19.
7
Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.钠-葡萄糖协同转运蛋白2抑制剂对心血管和血压有显著影响：一类新型抗糖尿病药物。
Drugs Today (Barc). 2017 Mar;53(3):191-202. doi: 10.1358/dot.2017.53.3.2555985.
8
9
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.2型糖尿病的药物治疗：现有疗法
Am J Med. 2017 Jun;130(6S):S4-S17. doi: 10.1016/j.amjmed.2017.04.004.
10
Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.2型糖尿病患者中与二肽基肽酶-4抑制剂及其他抗糖尿病药物相关的心血管疾病风险：一项全国性纵向研究
Cardiovasc Diabetol. 2016 Mar 1;15:41. doi: 10.1186/s12933-016-0350-4.
引用本文的文献
1
Factors Associated with the Utilization of Out-of-Region Medical Institutions for Brain Diseases.与脑部疾病患者选择外地医疗机构就医相关的因素
Yonsei Med J. 2025 Sep;66(9):599-608. doi: 10.3349/ymj.2024.0510.
2
Systemic Immune-Inflammation Index and Related Hematologic Markers as Prognostic Tools in Type 2 Diabetes.全身免疫炎症指数及相关血液学标志物作为2型糖尿病的预后评估工具
Medicina (Kaunas). 2025 Aug 9;61(8):1433. doi: 10.3390/medicina61081433.
3
Age-Related Characteristics of Diastolic Dysfunction in Type 2 Diabetes Patients.2型糖尿病患者舒张功能障碍的年龄相关特征
J Clin Med. 2025 Aug 15;14(16):5772. doi: 10.3390/jcm14165772.
4
Comprehensive analysis of risk factors associated with carotid plaque in patients with type 2 diabetes mellitus.2型糖尿病患者颈动脉斑块相关危险因素的综合分析。
World J Diabetes. 2025 Aug 15;16(8):104180. doi: 10.4239/wjd.v16.i8.104180.
5
Identification and mechanistic insights of ubiquitin-proteasome system and pyroptosis-related biomarkers in type 2 diabetes mellitus.2型糖尿病中泛素-蛋白酶体系统和细胞焦亡相关生物标志物的鉴定及机制研究
World J Diabetes. 2025 Aug 15;16(8):104879. doi: 10.4239/wjd.v16.i8.104879.
6
Prevalence and Hospitalization Trends of Cardiovascular Disease in Diabetic Populations: An Analysis of the United States Diabetes Surveillance System (USDSS) Data From 2000 to 2022.糖尿病患者心血管疾病的患病率及住院趋势：对2000年至2022年美国糖尿病监测系统（USDSS）数据的分析
Cureus. 2025 Jul 14;17(7):e87886. doi: 10.7759/cureus.87886. eCollection 2025 Jul.
7
4'-Methoxyresveratrol Improves Hepatic Insulin Resistance Induced by a High-Fat-Diet via Anti-Oxidative-Stress Activity.4'-甲氧基白藜芦醇通过抗氧化应激活性改善高脂饮食诱导的肝脏胰岛素抵抗。
Diabetes Metab Syndr Obes. 2025 Aug 8;18:2739-2752. doi: 10.2147/DMSO.S535103. eCollection 2025.
8
Novel approaches and applications in identifying DNA methylation markers of cardio-kidney-metabolic disease.识别心肾代谢疾病DNA甲基化标志物的新方法与应用
Epigenomics. 2025 Aug 12:1-16. doi: 10.1080/17501911.2025.2540273.
9
Incidence and predictors of diabetic kidney disease among type 2 diabetes mellitus adult patients in Ethiopia: a systematic review and meta-analysis.埃塞俄比亚2型糖尿病成年患者中糖尿病肾病的发病率及预测因素：一项系统评价和荟萃分析
BMC Endocr Disord. 2025 Aug 1;25(1):190. doi: 10.1186/s12902-025-02006-y.
10
Expert Consensus Statement on Simplified Glycemic Care in Patients With Type 2 Diabetes Mellitus.2型糖尿病患者简化血糖管理专家共识声明
Cureus. 2025 Jun 29;17(6):e87002. doi: 10.7759/cureus.87002. eCollection 2025 Jun.
本文引用的文献
1
Comparison of American and European Guidelines for Primary Prevention of Cardiovascular Disease: JACC Guideline Comparison.美国和欧洲心血管疾病一级预防指南比较：JACC 指南比较。
J Am Coll Cardiol. 2022 Apr 5;79(13):1304-1313. doi: 10.1016/j.jacc.2022.02.001.
2
New insights of cardiovascular and renal protection in diabetic chronic kidney disease with finerenone.非奈利酮对糖尿病慢性肾脏病心血管和肾脏保护的新见解
Cardiovasc Res. 2022 Mar 25;118(5):e36-e37. doi: 10.1093/cvr/cvac024.
3
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.依基线糖化血红蛋白和胰岛素使用情况评估慢性肾脏病和 2 型糖尿病患者的非奈利酮治疗效果：来自 FIDELIO-DKD 研究的分析。
Diabetes Care. 2022 Apr 1;45(4):888-897. doi: 10.2337/dc21-1944.
4
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.在 2 型糖尿病合并慢性肾脏病患者中，用非奈利酮治疗的心血管和肾脏结局：FIDELITY 汇总分析。
Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777.
5
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association.美国心脏协会关于 2 型糖尿病成人心血管危险因素综合管理的科学声明
Circulation. 2022 Mar;145(9):e722-e759. doi: 10.1161/CIR.0000000000001040. Epub 2022 Jan 10.
6
6. Glycemic Targets: Standards of Medical Care in Diabetes-2022.6. 血糖目标：2022 年糖尿病医学护理标准。
Diabetes Care. 2022 Jan 1;45(Suppl 1):S83-S96. doi: 10.2337/dc22-S006.
7
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.10. 心血管疾病和风险管理：2022 年糖尿病医学护理标准。
Diabetes Care. 2022 Jan 1;45(Suppl 1):S144-S174. doi: 10.2337/dc22-S010.
8
Tirzepatide Tested for Type 2 Diabetes With High Cardiovascular Risk.替尔泊肽用于心血管风险高的2型糖尿病的试验。
JAMA. 2021 Dec 28;326(24):2464. doi: 10.1001/jama.2021.22775.
9
SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs.SGLT-2 抑制剂在伴有或不伴有 2 型糖尿病的患者中的心血管和肾脏结局：11 项心血管结局试验的荟萃分析。
Cardiovasc Diabetol. 2021 Dec 16;20(1):236. doi: 10.1186/s12933-021-01430-3.
10
Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.降压与新发 2 型糖尿病风险：一项个体参与者数据荟萃分析。
Lancet. 2021 Nov 13;398(10313):1803-1810. doi: 10.1016/S0140-6736(21)01920-6.
Zotero 插件